GlobeNewsWire
08 Nov 2025, 16:30 UTC · 45w ago
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Verdict
Headline takes no side. We score GLUE +0.80 — strongly bullish.
- Expected · GLUE
+0.80strongly bullish
−1 bearish0bullish +1More positive than 85% of ticker scores this week

